Harrow Health logo

Harrow Health

HROW | NASDAQ
Chart Builder DCF Calculator
$29.09
-$1.03 (-3.42%)
At close: Nov 16, 2026, 4:00 PM ET
$29.00
-$0.09 (-0.31%)
After-hours: Nov 16, 2026, 7:30 PM ET
-3.42%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
52.6
+0.2 pts
Fundamentals Average
Market Sentiment Bullish
Moat Narrow
Sector Rank #224/1021 (Top 22%)

Key Statistics

Market Data

Market Cap $1.09B
1D Range
29.00 30.39
52W Range
26.04 54.80

Valuation (TTM)

PE -37.78
PB 37.41
EV/EBITDA 78.79

Valuation (NTM)

Forward PE 3,114.92
Forward PEG 0.06
Price Target $45.00
Loading financial charts...

Profile

Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing...

Sector Healthcare
Employees 373
IPO Date Sep 28, 2007
Fiscal Year January - December

Latest News

Harrow: Strong Revenue Growth And Operating Leverage Ahead

23 hours ago · seekingalpha.com

Harrow: Strong Revenue Growth And Operating Leverage Ahead
Harrow to Participate in Two Investor Conferences in November

4 days ago · globenewswire.com

Harrow to Participate in Two Investor Conferences in November
Harrow, Inc. (HROW) Q3 2026 Earnings Call Transcript

6 days ago · seekingalpha.com

Harrow, Inc. (HROW) Q3 2026 Earnings Call Transcript
Harrow Q3 Earnings Call Highlights

6 days ago · marketbeat.com

Harrow Q3 Earnings Call Highlights
Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say

7 days ago · zacks.com

Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say
Harrow (HROW) Q3 Earnings Lag Estimates

7 days ago · zacks.com

Harrow (HROW) Q3 Earnings Lag Estimates
Harrow Announces Third Quarter 2026 Financial Results

7 days ago · globenewswire.com

Harrow Announces Third Quarter 2026 Financial Results
Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?

15 days ago · zacks.com

Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?
Harrow Launches HarrowRx Platform

15 days ago · globenewswire.com

Harrow Launches HarrowRx Platform
Harrow's Top Two Drugs Alone Can Justify Its Current Valuation

19 days ago · seekingalpha.com

Harrow's Top Two Drugs Alone Can Justify Its Current Valuation

Earnings

Latest Earnings
Nov 9, 2026
EPS
$0.25
Beat +28.60%
REV
$99.3M
Beat +0.71%
Next Earnings
Mar 1, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
4
Consensus
Buy
Price Target
$45.00
Upside
+54.69%
Buy (4)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.